InsiderSignal.AI

InsiderSignal.ai

NUVB - Nuvation Bio Inc.

Insider Sale by Wentworth Kerry (Chief Regulatory Officer)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

5 days ago, Wentworth Kerry, serving as Chief Regulatory Officer at Nuvation Bio Inc. (NUVB), sold 36,750 shares at $5.01 per share, for a total transaction value of $184,279.00. Following this transaction, Wentworth Kerry now holds 53,000 shares of NUVB.

This sale represents a 41.00% decrease in Wentworth Kerry's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, April 17, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, April 21, 2026, 4 days after the trade was made.

Nuvation Bio Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Wentworth Kerry

Wentworth Kerry

Chief Regulatory Officer

Kerry A. Wentworth is the Chief Regulatory Officer at Nuvation Bio Inc., a biopharmaceutical company focused on oncology drug development[[2]](https://investors.nuvationbio.com/news/news-details/2022/Nuvation-Bio-Appoints-David-Liu-M.D.-Ph.D.-as-Chief-Medical-Officer-and-Kerry-Wentworth-as-Chief-Regulatory-Officer/default.aspx). She joined the company in 2022 and brings over 25 years of experience in domestic and international regulatory and quality affairs across multiple therapeutic areas including oncology, osteoarthritis, pain management, autoimmune disorders, and rare diseases[[3]](https://nuvationbio.com/management-team/). Her expertise spans both early and late-stage development, with broad product knowledge ranging from injectable small molecules to complex autologous platforms[[3]](https://nuvationbio.com/management-team/). Wentworth's career includes executive leadership positions at several prominent biopharmaceutical companies[[2]](https://investors.nuvationbio.com/news/news-details/2022/Nuvation-Bio-Appoints-David-Liu-M.D.-Ph.D.-as-Chief-Medical-Officer-and-Kerry-Wentworth-as-Chief-Regulatory-Officer/default.aspx). Most recently, she served as Chief Regulatory Officer at Flexion Therapeutics, where she was instrumental in leading the company's first New Drug Application (NDA) successfully through FDA approval and into commercialization before the company's acquisition by Pacira Biosciences in 2021[[2]](https://investors.nuvationbio.com/news/news-details/2022/Nuvation-Bio-Appoints-David-Liu-M.D.-Ph.D.-as-Chief-Medical-Officer-and-Kerry-Wentworth-as-Chief-Regulatory-Officer/default.aspx)[[3]](https://nuvationbio.com/management-team/). Prior to that role, she held positions as Vice President of Clinical, Regulatory, and Quality at Agenus Inc., where she led global regulatory and clinical development efforts, and previously directed regulatory functions at Genelabs Technologies and Genzyme[[2]](https://investors.nuvationbio.com/news/news-details/2022/Nuvation-Bio-Appoints-David-Liu-M.D.-Ph.D.-as-Chief-Medical-Officer-and-Kerry-Wentworth-as-Chief-Regulatory-Officer/default.aspx)[[3]](https://nuvationbio.com/management-team/). Wentworth holds a B.S. in pre-veterinary medicine from the University of New Hampshire[[3]](https://nuvationbio.com/management-team/). She also serves on the Board of Directors at the Massachusetts Biotechnology Council[[1]](https://in.marketscreener.com/insider/KERRY-WENTWORTH-A01SES/).

View full insider profile →

Trade Price

$5.01

Quantity

36,750

Total Value

$184,279.00

Shares Owned

53,000

Trade Date

Friday, April 17, 2026

5 days ago

SEC Filing Date

Tuesday, April 21, 2026

Filed 4 days after trade

HEALTHCAREBIOTECHNOLOGY

About Nuvation Bio Inc.

Company Overview

No company information available
View news mentioning NUVB

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5829123

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime